Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

Videos

Michael Pishvaian, MD, PhD, Johns Hopkins University
Videos
Intra-Arterial Gemcitabine Showed Promise for Locally Advanced Pancreatic Cancer
08/10/2023
At the 2023 World Congress on Gastrointestinal Cancers, Michael Pishvaian, MD, PhD, shared data from the first interim analysis of a phase 3 study evaluating intra-arterial gemcitabine among patients with locally advanced pancreatic cancer.
At the 2023 World Congress on Gastrointestinal Cancers, Michael Pishvaian, MD, PhD, shared data from the first interim analysis of a phase 3 study evaluating intra-arterial gemcitabine among patients with locally advanced pancreatic cancer.
At the 2023 World Congress on...
08/10/2023
Oncology
Leony Antoun, MD, Gustave Roussy Cancer Campus
Videos
Effect of Molecular Profiling on Survival Among Patients With Biliary Tract Cancers
08/09/2023
At the 2023 World Congress on Gastrointestinal Cancers, Leony Antoun, MD, discusses the impact of molecular profiling on survival among patients with advanced biliary tract cancers.
At the 2023 World Congress on Gastrointestinal Cancers, Leony Antoun, MD, discusses the impact of molecular profiling on survival among patients with advanced biliary tract cancers.
At the 2023 World Congress on...
08/09/2023
Oncology

Advertisement

Bradley Monk, MD, University of Arizona School of Medicine
Videos
Mirvetuximab Soravtansine for Folate Receptor-Alpha High, Platinum-Resistant Ovarian Cancer
08/02/2023
Bradley Monk, MD, discusses the results from the phase 3 MIRASOL trial and shares insights about mirvetuximab soravtansine for folate receptor-alpha high, platinum-resistant ovarian cancer.
Bradley Monk, MD, discusses the results from the phase 3 MIRASOL trial and shares insights about mirvetuximab soravtansine for folate receptor-alpha high, platinum-resistant ovarian cancer.
Bradley Monk, MD, discusses the...
08/02/2023
Oncology
Maximilian Kloft, MD, Maastricht University
Videos
Relationship Between Tumor Infiltrating Immune Cells And Tumor Draining Lymph Nodes Among Patients With Esophageal Cancer
08/01/2023
At the 2023 World Congress on Gastrointestinal Cancers, Maximilian Kloft, MD, presented results from a study relating the tumor infiltrating lymphocytes and the tumor-draining lymph nodes in esophageal cancer.
At the 2023 World Congress on Gastrointestinal Cancers, Maximilian Kloft, MD, presented results from a study relating the tumor infiltrating lymphocytes and the tumor-draining lymph nodes in esophageal cancer.
At the 2023 World Congress on...
08/01/2023
Oncology

Advertisement

Kristen Ciombor, MD, Vanderbilt-Ingram Cancer Center
Videos
Checkpoint Inhibition for Patients With Colorectal Cancer and High Microsatellite Instability
08/01/2023
At the 2023 World Congress on Gastrointestinal Cancers, Kristen Ciombor, MD, discussed the opportunities for checkpoint inhibition among patients with colorectal cancer and high microsatellite instability.
At the 2023 World Congress on Gastrointestinal Cancers, Kristen Ciombor, MD, discussed the opportunities for checkpoint inhibition among patients with colorectal cancer and high microsatellite instability.
At the 2023 World Congress on...
08/01/2023
Oncology
Philip Philip, MD, Wayne State University
Videos
Next-Generation Sequencing for All Patients With Pancreatic Ductal Adenocarcinoma
08/01/2023
At the 2023 World Congress on Gastrointestinal Cancers, Philip Philip, MD, argued for doing next-generation sequencing for all patients with pancreatic ductal adenocarcinoma.
At the 2023 World Congress on Gastrointestinal Cancers, Philip Philip, MD, argued for doing next-generation sequencing for all patients with pancreatic ductal adenocarcinoma.
At the 2023 World Congress on...
08/01/2023
Oncology
Yu Sunakawa, MD, St. Marianna University School of Medicine
Videos
Modified FOLFOXIRI Plus Cetuximab as the First-Line Treatment for Patients With RAS Wild-Type Metastatic Colorectal Cancer
07/28/2023
At the 2023 ESMO World Congress on Gastrointestinal Cancers, Yu Sunakawa, MD, presented updated survival data from the phase 2 DEEPER trial, evaluating modified(m)-FOLFOXIRI plus cetuximab vs m-FOLFOXIRI plus bevacizumab among patients with...
At the 2023 ESMO World Congress on Gastrointestinal Cancers, Yu Sunakawa, MD, presented updated survival data from the phase 2 DEEPER trial, evaluating modified(m)-FOLFOXIRI plus cetuximab vs m-FOLFOXIRI plus bevacizumab among patients with...
At the 2023 ESMO World Congress...
07/28/2023
Oncology

Advertisement

Federica Marmorino, MD, University of Pisa
Videos
Effect of Gut Microbiome Composition on Atezolizumab Efficacy Among Patients With Colorectal Cancer
07/28/2023
At the 2023 World Congress on Gastrointestinal Cancers, Federica Marmorino, MD, discusses the effect the gut microbiome composition may have on the efficacy of checkpoint inhibitors like atezolizumab for colorectal cancer.
At the 2023 World Congress on Gastrointestinal Cancers, Federica Marmorino, MD, discusses the effect the gut microbiome composition may have on the efficacy of checkpoint inhibitors like atezolizumab for colorectal cancer.
At the 2023 World Congress on...
07/28/2023
Oncology

Advertisement

Advertisement

Advertisement

Recent News

News
Tumor Mutational Status May Predict Recurrence, Survival Patterns for Patients With Early-Stage Non-Small Cell Lung Cancer
11/18/2024
According to results from a retrospective analysis, tumor mutational status can potentially predict recurrence and survival patterns for patients with surgically resected, stage I non-small cell lung cancer.
According to results from a retrospective analysis, tumor mutational status can potentially predict recurrence and survival patterns for patients with surgically resected, stage I non-small cell lung cancer.
According to results from a...
11/18/2024
Oncology
News
FDA Grants Approval to Revumenib for Patients With R/R Acute Leukemia With KMT2A Translocation
11/17/2024
On November 15, 2024, the FDA approved menin inhibitor revumenib for adult and pediatric patients 1 year and older with relapsed/refractory acute leukemia with KMT2A translocation.
On November 15, 2024, the FDA approved menin inhibitor revumenib for adult and pediatric patients 1 year and older with relapsed/refractory acute leukemia with KMT2A translocation.
On November 15, 2024, the FDA...
11/17/2024
Oncology
News
Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer
11/14/2024
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective...
11/14/2024
Oncology
News
Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer
11/14/2024
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the...
11/14/2024
Oncology
News
Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma
11/13/2024
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2...
11/13/2024
Oncology
News
Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
11/12/2024
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial,...
11/12/2024
Oncology
News
Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer
11/12/2024
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from...
11/12/2024
Oncology
News
Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer
11/11/2024
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a...
11/11/2024
Oncology
FDA Approval
FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia
11/08/2024
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA...
11/08/2024
Oncology
News
Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer
11/07/2024
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus...
11/07/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use